3-azaspiro[5.5]undecane hydrochloride
3-azaspiro[5.5]undecane hydrochloride Basic information
- Product Name:
- 3-azaspiro[5.5]undecane hydrochloride
- Synonyms:
-
- 3-azaspiro[5.5]undecane hydrochloride
- 4,4-Pentamethylenepiperidine
- 9-azaspiro[5.5]undecane chloride
- 3-Azaspiro[5.5]undecane HCl
- 4,4-Pentamethylenepiperidine HCl
- hydrochloride - [A81406]
- CAS:
- 1125-01-5
- MF:
- C10H20ClN
- MW:
- 189.7255
- EINECS:
- 214-404-1
- Product Categories:
-
- Heterocycles
- Inhibitors
- Mol File:
- 1125-01-5.mol
3-azaspiro[5.5]undecane hydrochloride Chemical Properties
- storage temp.
- Inert atmosphere,Room Temperature
- solubility
- Soluble to 100 mM in water and to 100 mM in DMSO
- form
- Powder
- color
- White to off-white
3-azaspiro[5.5]undecane hydrochloride Usage And Synthesis
Uses
4,4-Pentamethylenepiperidine Hydrochloride is a M2 proton channel blocker. Inhibits influenza virus M2 protein (AM2).
Uses
A M2 proton channel blocker. Inhibits influenza virus M2 protein (AM2).
Synthesis
1130-32-1
1125-01-5
The synthesis of BL-1743 started with 3,3-cyclopentane glutarimide, which was first subjected to a reductive reaction with lithium aluminum hydride (LiAlH4) in tetrahydrofuran (THF) under refluxing conditions to afford 3-azaspiro[5,5]undecane hydrochloride (9), which was followed by treatment with HCl/ethyl ether to obtain the target product in 75% yield (see Scheme 1). Next, model compound BL-1743 was prepared by nucleophilic substitution of compound 9 by 2-methylthio-2-imidazoline.In addition, compound 9 was subjected to reductive amination with different aldehydes in dichloroethane using sodium triacetoxyborohydride (NaBH(OAc)3) and formic acid (HCO2H) as reducing agents to afford derivatives 1-8 in yields ranging from 65% to 95%. The results of activity tests showed that the inhibitory activity of BL-1743 was completely lost at 100 μM concentration after the imidazoline ring was replaced by a hydrophobic substituent or a heterocyclic ring that lacked a hydrogen bond donor (HBD), and the AM2 activity remained >90%. In contrast, inhibitors 7 and 8 containing an imidazole head group showed moderate inhibitory activity, suggesting that the presence of a hydrogen bond donor may be a structural feature necessary for inhibitory activity.
References
[1] Patent: US2010/69420, 2010, A1. Location in patent: Page/Page column 7
3-azaspiro[5.5]undecane hydrochlorideSupplier
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- +86 (0) 571 85 58 67 18
- Tel
- 021-50135380
- shchemsky@sina.com
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 021-24206007 13764915196
- sales@balmxy.com